ENSOCELL LTD is a research-oriented biotechnology company specializing in the development of innovative solutions targeting fibrosis – a group of debilitating diseases characterized by excessive collagen deposition and tissue damage. Located at The Eddeva Building, Cambridge, CB22 3AT, Ensocell operates as a Limited Liability Company (Ltd) with Reg: 14714531. Founded in 2023, the company is currently active and maintains a strong focus on intellectual property creation and commercialization of novel technologies. Ensocells’ core expertise lies within spatial-omics data analysis combined with advanced Artificial Intelligence/Machine Learning techniques. This allows for precise identification of disease drivers at an individual patient level, facilitating targeted drug development. The company's primary research area is the prediction of treatment response based on complex biological datasets – a crucial element in creating precision biologics. Furthermore, Ensocell actively pursues international collaborations and partnerships to expand its technological capabilities. The company’s staffing includes skilled workers with high performance ratings, demonstrating a commitment to innovation. The strategic focus encompasses a range of SIC codes including -72110 (Research and experimental development on biotechnology) and potentially other relevant industry classifications depending on specific activities.

ENSOCELL LTD is a research-oriented biotechnology company specializing in the development of innovative solutions targeting fibrosis – a group of debilitating diseases characterized by excessive collagen deposition and tissue damage. Located at The Eddeva Building, Cambridge, CB22 3AT, Ensocell operates as a Limited Liability Company (Ltd) with Reg: 14714531. Founded in 2023, the company is currently active and maintains a strong focus on intellectual property creation and commercialization of novel technologies. Ensocells’ core expertise lies within spatial-omics data analysis combined with advanced Artificial Intelligence/Machine Learning techniques. This allows for precise identification of disease drivers at an individual patient level, facilitating targeted drug development. The company's primary research area is the prediction of treatment response based on complex biological datasets – a crucial element in creating precision biologics. Furthermore, Ensocell actively pursues international collaborations and partnerships to expand its technological capabilities. The company’s staffing includes skilled workers with high performance ratings, demonstrating a commitment to innovation. The strategic focus encompasses a range of SIC codes including -72110 (Research and experimental development on biotechnology) and potentially other relevant industry classifications depending on specific activities.